Zydus Wellness

ZYDUSWELL closed at ₹470.00 on 2026-11-06, reflecting a -1.0% daily decline after a wide intraday range (+14.9%) and a significant volume surge on 2026-11-03. The technical setup is defined by a conflict between short-term weakness and longer-term structure. On the daily chart, price sits below all key moving averages (EMA/SMA 20/50/200) and the Supertrend, which is bearish, with an ADX of 23.23 indicating developing but not yet strong trend conviction. Conversely, the monthly timeframe remains bullish, with price above its moving averages and Supertrend, supported by an established trend (ADX 30.4). The stock is trading near the lower end of its 20-day and 50-day ranges (+21.5% and +12.3% respectively) but in the middle of its 252-day range (+41.9%). Current drawdown stands at -22.0%, with annualized volatility at 35.9%. Immediate resistance lies at ₹483.45 (pivot) and ₹485.52 (high), while support is found at ₹461.05 and ₹458.70.

Zydus Wellness Ltd reported its Q2 FY27 results for the period ending September 2026, revealing a significant divergence between top-line growth and bottom-line profitability. Revenue surged 73.2% to ₹1,126.6 crore, driven by double-digit growth in key brands such as Sugar Free, Nutralite, and Everyuth. This expansion contributed to an EBITDA margin improvement of 400 basis points year-on-year, reaching 7.6%. However, the company’s profit after tax (PAT) was limited to ₹5 crore, a sharp reversal from the ₹53 crore loss recorded in the same quarter last year. This modest profit figure reflects the impact of exceptional costs associated with the liquidation of Naturell (India) Pvt Ltd and the acquisition of Comfort Click Ltd, alongside one-time impacts from new labour codes. Despite these headwinds, an exceptional gain of ₹7 crore aided the final PAT figure. Following the announcement on November 3, 2026, the stock price rose 8%, indicating market reaction to the revenue surge and margin expansion despite the profit constraints.

Zydus Wellness Limited reported unaudited financial results for the quarter and half-year ended September 30, 2026, alongside a press release detailing significant growth in sales and profitability. For Q2 FY27, net sales rose 74.6% to ₹11,227 million from ₹6,429 million in the prior-year period, while EBITDA increased 271.7% to ₹855 million. Half-year H1 FY27 sales reached ₹25,526 million (up 70.1%) with EBITDA at ₹3,272 million (up 83.2%). The company also addressed regulatory scrutiny, confirming receipt of an FSSAI notice regarding alleged misleading product claims on September 24, 2026, and submitted a response asserting factual and scientifically substantiated label statements. The company stated there is no material impact from this news article.

Zydus Wellness is navigating a significant capital expansion phase, evidenced by borrowings rising from ₹188 crore in Mar 2025 to ₹3,167 crore by Sep 2026, while Fixed Assets grew to ₹8,602 crore. This leverage has materially impacted earnings quality; despite TTM sales of ₹5,013 crore (up 74% YoY in Q2 FY2026-27), interest costs surged to ₹133 crore (TTM) and ₹27.2 crore in the latest quarter, compressing net profit to just ₹5.1 crore in Q2 FY2026-27 against ₹119 crore in Q1. Cash conversion has weakened, with CFO/EBITDA dropping to 50% in Mar 2026 and cash reserves falling sharply to ₹36.7 crore as of Sep 2026. While promoter holding remains stable at ~69.6%, the combination of high debt servicing, declining cash buffers, and low ROCE (5%) suggests the company is in a heavy investment cycle where top-line growth has not yet translated into bottom-line resilience.

Zydus Wellness reported a significant operational turnaround in Q2 FY27, with revenue surging 73.2% year-on-year to ₹1,126.6 crore and EBITDA margins expanding by 400 basis points to 7.6%. Net profit turned positive at ₹5 crore, reversing a ₹53 crore loss in the prior-year period, aided by an exceptional gain of ₹7 crore. This fundamental improvement triggered an 8% share price jump post-results. Technically, while daily trends remain bearish with the stock trading at ₹470.0 (a current drawdown of -22.0%), the monthly and weekly charts show bullish supertrend directions, suggesting longer-term structural support. The constructive case hinges on whether sustained double-digit growth across key brands like Sugar Free and Nutralite can offset recent one-time costs from the Naturell liquidation and Comfort Click acquisition.

Zydus Wellness faces significant near-term headwinds despite recent revenue growth. The company’s Q2 FY27 net profit was just ₹5 crore, heavily weighed down by exceptional expenses from the liquidation of Naturell (India) Pvt Ltd and the acquisition of Comfort Click Ltd, alongside one-time impacts from new labour codes. While EBITDA margins expanded to 7.6%, this remains a modest level for a consumer wellness brand. From a market perspective, the stock is in a pronounced downtrend on daily timeframes, with the Supertrend indicator signaling bearish momentum. The share price has suffered a current drawdown of -22.0% against a maximum historical drawdown of -28.8%, reflecting substantial investor erosion over the past six months (-7.5%) and three months (-11.6%). Technical resistance is immediate at ₹483.45, just 2.86% above the current close of ₹470.00, suggesting limited upside room without a clear reversal signal.